Eiger BioPharmaceuticals 2017-06-30T18:30:18+00:00

IN THE NEWS
1809, 2017

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors - Company Advancing Multiple Programs in Orphan Disease Pipeline PALO ALTO, Calif., September 18, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Evan Loh, MD to its Board of Directors.  Dr. Loh’s clinical development and regulatory experience spans nearly two decades across all phases of development ranging from discovery to registration, [...]

509, 2017

Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PALO ALTO, Calif., Sept 5, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan designation for pegylated interferon lambda 1a (Lambda) as a potential treatment for chronic hepatitis delta virus (HDV) infection. The mission of the FDA Office of Orphan Products Development [...]

3008, 2017

Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences

Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences PALO ALTO, Calif. – August 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at two upcoming meetings in September in New York City. The 24th Annual BioCentury NewsMakers in the Biotech Industry Healthcare Conference at 11:30 am ET on Friday, September 8, [...]